Dr. Smith is a clinically trained neuropsychologist with more than thirty years’ experience in clinical trials involving cognition. Dr. Smith has been an investigator in over 100 clinical trials in Alzheimer’s disease, vascular dementia, Parkinson’s disease, and mild cognitive impairment. He also has experience in other indications such as depression, epilepsy, migraine, and chronic pain. Dr. Smith has published extensively in Alzheimer’s Disease, and has been an advisor to a number of pharmaceutical companies regarding development of research protocols and post marketing issues. Dr. Smith has carried out training at numerous investigator meetings, and has extensively trained hospital dementia teams in the development of treatment protocols for the prescription of acetyl-cholinesterase inhibitors. Since 2007, he has worked with several CRO’s, running dementia programmes, and since 2019, he has been an advisor to Eisai, for the Phase III Ban2401 clinical trial in Early Alzheimer’s Disease, which has recently been fast-tracked for approval by the FDA.